Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 5, 2010, Pages 1918-1923

  Sarafraz Yazdi, Ehsan ^a   Bowne, Wilbur B ^a   Adler, Victor ^b   Sookraj, Kelley A ^a,b   Wu, Vernon ^a   Shteyler, Vadim ^a   Patel, Hunaiz ^a   Oxbury, William ^a   Brandt Rauf, Paul ^c   Zenilman, Michael E ^a   Michl, Josef ^a   Pincus, Matthew R ^a,b  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2; PROTEIN P53; PROTEIN PNC 27; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; BINDING SITES; CELL DEATH; CELL LINE; CELL LINE, TUMOR; CELL MEMBRANE; CRYSTALLOGRAPHY, X-RAY; FEMALE; FLUORESCENT DYES; HUMANS; MALE; MICROSCOPY, CONFOCAL; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PEPTIDE FRAGMENTS; PLASMIDS; PROTEIN CONFORMATION; PROTO-ONCOGENE PROTEINS C-MDM2; RECOMBINANT FUSION PROTEINS; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 76649141217     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0909364107     Document Type: Article

References (22)

1. Kanovsky M, et al. (2001) Peptides from the amino terminal mdm-2 binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells. Proc Natl Acad Sci USA, 98:12438-12443.
2. Do TN, et al. (2003) Preferential induction of necrosis in human breast cancer cells by a p53 peptide derived from the mdm-2 binding site. Oncogene, 22:1431-1444.
3. Pincus MR, Michl J, Bowne W, Zenilman M (2007) Anti-cancer peptides from the ras-p21 and p53 proteins. Research Advances in Cancer, ed Mohan R (Global Research Network Publishers, Kerala, India), pp 65-90.
4. Bowne WB, et al. (2008) The penetratin sequence in the anticancer PNC-28 peptide causes tumor necrosis rather than apoptosis of human pancreatic cancer cells. Ann Surg Oncol, 15:3588-3600.
5. Michl J, et al. (2006) PNC-28, a p53 peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growth in vivo. Int J Cancer, 119:1577-1585.
6. Picksley SM, Spicer JF, Barnes DM, Lane DP (1996) The p53-MDM2 interaction in a cancer-prone family, and the identification of a novel therapeutic target. Acta Oncol, 35:429-434.
7. Bottger V, et al. (1996) Identification of novel mdm2 binding peptides by phage display. Oncogene, 13:2141-2147.
8. Wasylyk C, et al. (1999) p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53. Oncogene, 18:1921-1934.
9. Chene P, Fuchs J, Carena I, Furet P, Garcia-Echeverria C (2002) Study of the cytotoxic effect of a peptidic inhibitor of the p53-hdm2 interaction in tumor cells. Febs Lett, 529:293-297.
10. Harbour JW, Worley L, Ma D, Cohen M (2002) Transducible peptide therapy for uveal melanoma and retinoblastoma. AMA Arch Ophthalmol, 120:1341-1346.
11. Vassilev LT, et al. (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science, 303:844-848.
12. Rosal R, et al. (2004) NMR solution structure of a peptide from the mdm-2 binding domain of the p53 protein that is selectively cytotoxic to cancer cells. Biochemistry, 43:1754-1861.
13. Pincus MR (2001) The Physiological Structure and Function of Proteins in Principles of Cell Physiology, ed Sperelakis N (Academic, New York), 3rd Ed, pp 19-42.
14. Dathe M, Wieprecht T (1999) Structural features of helical anti-microbial peptides: Their potential to modulate activity on model membranes and biological cells. Biochem Biophys Acta, 1462:71-87.
15. Kussie PH, et al. (1996) Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science, 274:921-922.
16. Bertrand R, Solary E, O'Connor P, Kohn KW, Pommier Y (1994) Induction of a common pathway of apoptosis by staurosporine. Exp Cell Res, 211:314-321.
17. Manne V, et al. (1995) Ras farnesylation as a target for novel antitumor agents: Potent and selective farnesyl diphosphate analogue inhibitors of farnesyltransferase. Drug Dev Res, 34:121-137.
18. Yang J-Y, et al. (2006) MDM2 promotes cell motility and invasiveness by regulating E-cahedrin degradation. Mol Cell Biol, 26:7269-7282.
19. Toth A, Nickson P, Qin LL, Erhardt P (2006) Differential regulation of cardiomyocyte survival and hypertrophy by MDM2, an E3 ubiquitin ligase. J Biol Chem, 281: 3679-3689.
20. Sookraj K, et al. (2009) The anticancer peptide, PNC-27, induces tumor cell lysis as the intact peptide. Cancer Chemoth Pharm, in press.
21. Palmer M, Valeva A, Kehoe M, Bhakdi S (1995) Kinetics of streptolysin O self-assembly. Eur J Biochem, 231:388-395.
22. Ramjeesingh M, Kidd JF, Huan LJ, Wang Y, Bear CE (2003) Dimeric cystic fibrosis transmembrane conductance regulator exists in the plasma membrane. Biochem J, 374:797-797.